# Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2

> **NCT03454048** · NA · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 24 (actual)

## Conditions studied

- Malaria,Falciparum
- Gametocytes
- Controlled Human Malaria Infection
- Transmission

## Interventions

- **DRUG:** Piperaquine (low dose)
- **DRUG:** Piperaquine (high dose)
- **DRUG:** Sulfadoxine pyrimethamine
- **DRUG:** Atovaquone Proguanil
- **OTHER:** malaria challenge infection, P. falciparum 3D7
- **OTHER:** Blood stage malaria challenge infection, P. falciparum 3D7

## Key facts

- **NCT ID:** NCT03454048
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-07
- **Primary completion:** 2018-11-01
- **Final completion:** 2018-11-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-07-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03454048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03454048, "Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03454048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*